Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
PLX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Protalix BioTherapeutics, Inc.AMEX: PLX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 34.0% from a year ago
Short-term investments stood at $10.08M at the end of Q1 FY2026, down 34.0% from a year earlier and down 35.3% from the prior quarter. Over 3 fiscal years it compounded at +45.4% a year.
Context
- Short-term investments amounted to 9.9% of total assets at the end of Q1 FY2026, down 10.8 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -34.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 15.59M USD
- Year-over-year change
- +3.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.59M | +3.5% |
| FY2024 | 2024-12-31 | 15.07M | -28.0% |
| FY2023 | 2023-12-31 | 20.93M | +312.8% |
| FY2022 | 2022-12-31 | 5.07M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How PLX compares with its peers on the latest reported figures
- PLX's Mar 2026 short-term investments of $10.08M is the 3rd highest of the 4 companies compared; the peer median is $117.8M.
- Its year-over-year change of -34.0% is the 2nd highest of 3, against a peer median of +57.2%.
- Short-term investments amounts to 9.9% of total assets for PLX, versus a peer median of 18.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $238M | -35.2% | -25.0% | 18.4% | |
| Mar 2026 | $117.8M | +149.7% | — | 24.1% | |
| Mar 2026 | $10.08M | -34.0% | +45.4% | 9.9% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding PLX) | $117.8M | +57.2% | -25.0% | 18.4% | |
Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38.99M | 17.11M | 23.63M | 19.76M | 14.68M |
| Short-term Investments | 0 | 5.07M | 20.93M | 15.07M | 15.59M |
| Net Receivables | 3.44M | 4.59M | 5.27M | 2.91M | 8.84M |
| Inventory | 17.95M | 16.8M | 19.05M | 21.24M | 25.73M |
| Other Current Assets | 380K | 536K | 611K | 596K | 1.44M |
| Total Current Assets | 61.67M | 44.88M | 69.93M | 60.08M | 66.67M |
| Property, Plant & Equipment (Net) | 9.92M | 9.64M | 10.88M | 10.02M | 12.58M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 3.09M | 2.86M | 2.52M |
| Other Non-current Assets | 2.08M | 1.27M | 528K | 462K | 578K |
| Total Non-current Assets | 12M | 10.91M | 14.5M | 13.34M | 15.67M |
| Total Assets | 73.67M | 55.79M | 84.43M | 73.42M | 82.35M |
| Account Payables | 6.99M | 5.86M | 4.32M | 4.53M | 5.26M |
| Short-term Debt | 0 | 0 | 21.66M | 0 | 0 |
| Tax Payables | 0 | 530K | 2.88M | 3.48M | 0 |
| Deferred Revenue | 8.55M | 13.18M | 0 | 0 | 0 |
| Other Current Liabilities | 1.51M | 11.06M | 4.94M | 1.81M | 2.31M |
| Total Current Liabilities | 33.18M | 32.43M | 45.53M | 25.62M | 26.52M |
| Long-term Debt | 27.89M | 28.19M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 11.79M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.47M | 1.64M | 714K | 559K | 661K |
| Total Non-current Liabilities | 46.53M | 34M | 5.34M | 4.59M | 7.6M |
| Total Liabilities | 79.7M | 66.43M | 50.87M | 30.21M | 34.12M |
| Common Stock | 46K | 54K | 73K | 76K | 80K |
| Retained Earnings | (374.93M) | (389.86M) | (381.55M) | (378.39M) | (385M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (6.04M) | (10.64M) | 33.57M | 43.21M | 48.23M |
| Total Debt | 33.47M | 33.47M | 27.69M | 5.53M | 8.32M |
| Net Debt | (5.52M) | 16.36M | 4.06M | (14.23M) | (6.36M) |
Protalix BioTherapeutics, Inc.
AMEX:PLX
Intrinsic Alpha fair value
Locked
Current Price
$3.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.